Harvard Pilgrim Health Care Home
  Learn more.
  Sign up for HPHConnect.
Medical Management
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Office Support
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

April 2016

Specialty Pharmacy Program Updates

Harvard Pilgrim’s Specialty Pharmacy Program has added the following medications for the Premium and Value formularies.

Name Indication Coverage Available From

Adynovate [antihemophilic factor, (recombinant) PEGylated]

Adynovate is a human antihemophilic factor indicated in patients age 12 and older with hemophilia A (congenital factor VIII deficiency) used for:

• On-demand treatment and control of bleeding episodes
• Routine prophylaxis to reduce the frequency of bleeding episodes

Adynovate is not indicated for the treatment of von Willebrand disease. 
Medical Accredo

Alecensa (alectinib) 

Alecensa is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small-cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. 

Pharmacy Accredo

Cotellic (cobimetinib)

Cotellic is a kinase inhibitor used, in combination with vemurafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.

Pharmacy Accredo

Ninlaro (ixazomib) 

Ninlaro is a proteasome inhibitor used with lenalidomide and dexamethasone to treat patients with multiple myeloma who have received at least one prior therapy.

Pharmacy Accredo

Nuwiq [antihemophilic factor, (recombinant)] 

Nuwiq is a recombinant antihemophilic factor indicated for the treatment and prophylaxis of bleeding in pediatric and adult patients with hemophilia A (congenital factor VIII deficiency). 

Medical  Accredo

Odomzo (sonidegib) 

Odomzo is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

Pharmacy Accredo

Tagrisso (osimertinib) 

Tagrisso, a kinase inhibitor, is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy.

Pharmacy Accredo

Uptravi (selexipag) 

Uptravi is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to slow disease progression and reduce the risk of hospitalization.

Pharmacy Accredo

Veltassa (patiromer) 

Veltassa is a potassium binder used to treat hyperkalemia.

Pharmacy  Walgreens Specialty Pharmacy

Zepatier (elbasvir/grazoprevir) 

Zepatier — a fixed-dose combination tablet containing elbasvir and grazoprevir — is indicated with or without ribavirin for treatment of chronic HCV genotypes 1 or 4 infection in adults. 

Pharmacy Accredo

Email this article to a colleague   

Network Matters Archives

Download printer-friendly version


Important Referral Reminders for PCPs

New Medicare Advantage FDR Compliance Program Website Available


Vaccine Policy: Updates Regarding State-Supplied Vaccines

Clinical Policy and Prior Authorization Updates

Upcoming Clinical Reviews: Give Us Your Feedback

Updates to Harvard Pilgrim’s Nexium Coverage

Diabetes Outreach Program for Medicare Advantage Members

Harvard Pilgrim’s Commitment to Health Equity

P&T Committee Updates

Specialty Pharmacy Program Updates

Reminder Regarding Annual Well Visits


Benefit from the Convenience of Electronic Funds Transfer

Reminder: Use of Non-Participating Ambulance Providers


Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Vice President, Network Services

Annmarie Dadoly,

Joseph O'Riordan,

Kristin Edmonston,
Production Coordinator